Product Description
Mechanisms of Action: EGFR Inhibitor,ERBB2 Inhibitor,VEGFR Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|Brain Cancer|Glioblastoma|Polycystic Kidney Diseases|Kidney Diseases, Cystic|Polycystic Kidney, Autosomal Dominant|Arthrogryposis|Meningeal Cancer|Meningeal Carcinomatosis|Breast Cancer
Phase 1: Oncology Solid Tumor Unspecified|Gastrointestinal Cancer|Breast Cancer|Esophageal Cancer|Polycystic Kidney, Autosomal Recessive|Non-Small-Cell Lung Cancer|Polycystic Kidney Diseases|Kidney Diseases, Cystic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| KD019-103 | P1 |
Completed |
Polycystic Kidney Diseases|Kidney Diseases, Cystic|Polycystic Kidney, Autosomal Recessive |
2019-09-30 |
12% |
2022-05-12 |
Primary Endpoints|Start Date|Treatments |
| s14-01171 | P1 |
Withdrawn |
Gastrointestinal Cancer|Esophageal Cancer |
2017-07-01 |
2019-05-25 |
Treatments |
|
| XL647-002 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-08-01 |
2019-03-21 |
Treatments |
|
| XL647-003 | P1 |
Withdrawn |
Breast Cancer|Non-Small-Cell Lung Cancer |
2009-12-01 |
2019-03-18 |
Treatments |
|
| XL647-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2007-07-01 |
2019-03-21 |
Treatments |
|
| ACT17675 | P2 |
Completed |
Kidney Diseases, Cystic|Arthrogryposis|Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant |
2022-01-25 |
55% |
2023-02-07 |
Primary Endpoints |
| KD019-208 | P2 |
Completed |
Brain Cancer|Glioblastoma |
2020-04-30 |
50% |
2021-09-23 |
|
| KD019-101 | P2 |
Completed |
Arthrogryposis|Polycystic Kidney, Autosomal Dominant|Polycystic Kidney Diseases|Kidney Diseases, Cystic |
2019-02-08 |
37% |
2022-11-09 |
|
| KD019-206 | P2 |
Completed |
Brain Cancer|Non-Small-Cell Lung Cancer|Meningeal Carcinomatosis|Meningeal Cancer |
2018-04-03 |
50% |
2022-03-17 |
|
| KD019-207 | P2 |
Terminated |
Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant|Kidney Diseases, Cystic |
2016-12-21 |
2022-05-27 |
Primary Endpoints|Start Date|Treatments |
|
| KD019-204 | P2 |
Terminated |
Breast Cancer|Brain Cancer |
2015-09-13 |
2022-04-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| XL647-201 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2010-05-01 |
2019-03-21 |
Treatments |
|
| XL647-203 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2009-10-01 |
2019-03-21 |
Treatments |
|
| KD019-301 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-07-25 |
2024-06-28 |
Primary Endpoints|Treatments |